Computer Methods and Programs in Biomedicine
Volume 105, Issue 3 , Pages 194-209 , March 2012

Single stage and multistage classification models for the prediction of liver fibrosis degree in patients with chronic hepatitis C infection

  • Ahmed M. Hashem

      Affiliations

    • Department of Systems and Biomedical Engineering, Faculty of Engineering, Minia University, Minia, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +20 100 5109263; fax: +20 2 25292781.
    • ,
  • M. Emad M. Rasmy

      Affiliations

    • Department of Systems and Biomedical Engineering, Faculty of Engineering, Cairo University, Giza, Egypt
    • ,
  • Khaled M. Wahba

      Affiliations

    • Department of Systems and Biomedical Engineering, Faculty of Engineering, Cairo University, Giza, Egypt
    • ,
  • Olfat G. Shaker

      Affiliations

    • Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt

Received 29 July 2011 ,Revised 14 October 2011 ,Accepted 14 October 2011.

References 

  1. El-Zanaty F. Ann Way, Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International; March 2009;
  2. Saleh DA, Shebl F, Abdel-Hamid M, et al. Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. Trans. R. Soc. Trop. Med. Hyg. 2008;102(September (9)):921–928
  3. Gebo K, Herlong H, Torbenson M, et al. Role of liver biopsy in the management of chronic hepatitis C: a systematic review. Hepatology. 2002;36(November):161–172
  4. Cadranel J, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology. 2000;32(September (3)):477–481
  5. Regev A, Berho M, Jeffers L, Molina E, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002;9(October (10)):2614–2618
  6. Bedossa P, Dargère D. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(December (6)):1499–1557
  7. Esmat G, Metwally M, Zalata K, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. Hepatology. 2007;46(April (4)):620–627
  8. Moemen ME. Invasive versus non-invasive diagnosis of liver fibrosis (review article). Eg. J. Anaesth. 2008;24:363–370
  9. Pinzani M, Vizzuttet F, Arena U, et al. Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008;5(February (2)):95–106
  10. Montazeri G, Estakhri A, Mohamadnejad M, et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol. 2005;5:32–38
  11. Sakugawa H, Nakayohshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with non alcoholic fatty liver disease. World J. Gastroenterol. 2005;11:255–259
  12. Halfon P, Bourlière M, Pénaranda G, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Compar. Hepatol. 2005;4(July (6)):1–7
  13. Poynard T, Afdhal NH. Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis. Antivir. Ther. 2010;15(3):281–291
  14. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol. 2005;42(May (5)):615–624
  15. Mayer B, Rangwala H, Gupta R, et al. Feature mining for prediction of degree of liver fibrosis. In: AMIA Annu. Symp. Proc.. 2005;pp. 1048
  16. Cremilleux B, Durand N. Search for factors estimating the stage of liver fibrosis based on the discovery of meaningful clusters. In: PKDD 2002 Discovery Challenge on Hepatitis Data. Helsinki, Finland. 2002;
  17. Gorunescu F. Data mining techniques in computer-aided diagnosis: non-invasive cancer detection. World Acad. Sci. Eng. Technol. 2007;34:280–283
  18. Resino S, Seoane JA, Bellon JM, et al. An artificial neural network improves the noninvasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. J. Infect. 2011;62(January (1)):77–86
  19. Wang D, Wang Q, Shan F, et al. Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers. BMC Infect. Dis. 2010;10(August):251–258
  20. Dascalu G, Carausu E, Manuc D. Methods for data selection in medical databases: the binary logistic regression – relations with the calculated risks. World Acad. Sci. Eng. Technol. 2008;38(February):278–282
  21. Stoean R, Preuss M, Stoean C, et al. An evolutionary approximation for the coefficients of decision functions within a support vector machine learning strategy. Found. Comput. Intell. 2009;1:83–114
  22. Stoean R, Stoean C, Lupsor M, et al. Evolutionary-driven support vector machines for determining the degree of liver fibrosis in chronic hepatitis C. Artif. Intell. Med. 2011;51(1):53–65
  23. G. Mahajani, Y. Aslandogan, Evidence Combination in Medical Data Mining, Department of Computer Science and Engineering University of Texas at Arlington, U.S.A. Technical Report, 2003.
  24. Abdel-Hamid M, Edelman DC, Highsmith WE, Constantine NT. Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J. Hum. Virol. 1997;1(November (1)):58–65
  25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C, The METAVIR Cooperative Study Group. Hepatology. 1996;24(August (2)):289–293
  26. Allwein E, Schapire R, Singer Y. Reducing multiclass to binary: a unifying approach for margin classifiers. J. Mach. Learn. Res. 2000;1(December):113–141
  27. Groebner D, Shannon P, Fry P, Smith K. Business Statistics: A Decision Making Approach. Prentice Hall; 2008;pp. 679–748
  28. Howes P, Crook N. Using input parameter influences to support the decisions of feedforward neural networks. Neurocomputing. 2009;24:191–206
  29. McHutchison J, Blatt L, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology, Consensus Interferon Study Group. J. Gastroenterol. Hepatol. 2000;15(August (8)):945–951
  30. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J. Viral Hepatitis. 2002;9(March):128–133
  31. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357(April (9262)):1069–1075
  32. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology. 2001;34(November (5)):859–867
  33. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000;275(January (4)):2247–2250
  34. Murawaki Y, Ikuta Y, Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin. Chim. Acta. 1999;281(March (2)):109–120
  35. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 2002;277(March (13)):11069–11076
  36. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 2004;99(June (6)):1160–1174

PII: S0169-2607(11)00269-0

doi: 10.1016/j.cmpb.2011.10.005

Computer Methods and Programs in Biomedicine
Volume 105, Issue 3 , Pages 194-209 , March 2012

Article Tools

* Image Usage & Resolution